Lipoprotein abnormalities in patients with atherosclerotic renovascular disease

Kidney and Blood Pressure Research

Volumn 34, Issue 5, 2011, Pages 311-319

  Nowakowska Fortuna, Elzbieta ^a   Herlitz, Hans ^a   Saeed, Aso ^a   Attman, Per Ola ^a   Jensen, Gert ^a   Alaupovic, Petar ^b   Guron, Gregor ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Apolipoprotein C III; Atherosclerosis; Chronic kidney disease; Dyslipidemia; Renal artery stenosis; Renovascular disease

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN C3; ATORVASTATIN; CANDESARTAN; LIPOPROTEIN; PRAVASTATIN; RENIN; SIMVASTATIN;

ADULT; ANGIOPLASTY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC RENOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISORDERS OF LIPOPROTEIN METABOLISM; FEMALE; FOLLOW UP; HUMAN; MALE; PERCUTANEOUS TRANSLUMINAL RENAL ANGIOPLASTY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENOVASCULAR DISEASE;

AGED; APOLIPOPROTEIN C-III; APOLIPOPROTEINS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL ARTERY OBSTRUCTION; RENIN;

EID: 80955176307     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000325648     Document Type: Article

References (37)

1. Johansson M, Herlitz H, Jensen G, Rundqvist B, Friberg P: Increased cardiovascular mortality in hypertensive patients with renal artery stenosis: Relation to sympathetic activation, renal function and treatment regimens. J Hypertens 1999; 17: 1743-1750.
2. Wright JR, Shurrab AE, Cheung C, Waldek S, O'Donoghue DJ, Foley RN, Mamtora H, Kalra PA: A prospective study of the determinants of renal functional outcome and mortality in atherosclerotic renovascular disease. Am J Kidney Dis 2002; 39: 1153-1161. (Pubitemid 34591929)
3. Conlon PJ, Little MA, Pieper K, Mark DB: Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int 2001; 60: 1490-1497. (Pubitemid 32960044)
4. Scoble JE, de Takats D, Ostermann ME, Connolly JO, Scott NR, Beeso JA, Poyser KH, Peters TJ, Sherwood RA: Lipid profiles in patients with atherosclerotic renal artery stenosis. Nephron 1999; 83: 117-121. (Pubitemid 29447504)
5. Attman PO, Samuelsson O: Dyslipidemia of kidney disease. Curr Opin Lipidol 2009; 20: 293-299.
6. Alaupovic P: The concept of apolipoproteindefined lipoprotein families and its clinical significance. Curr Atheroscler Rep 2003; 5: 459-467. (Pubitemid 38906743)
7. Attman PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-592. (Pubitemid 23178473)
8. Chan DT, Irish AB, Dogra GK, Watts GF: Dyslipidaemia and cardiorenal disease: Mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis 2008; 196: 823-834.
9. Alaupovic P: Apolipoprotein composition as the basis for classifying plasma lipoproteins: Characterization of ApoA- and ApoB-containing lipoprotein families. Prog Lipid Res 1991; 30: 105-138. (Pubitemid 121002991)
10. Ginsberg HN: New perspectives on atherogenesis: Role of abnormal triglyceride-rich lipoprotein metabolism. Circulation 2002; 106: 2137-2142. (Pubitemid 35192822)
11. Lee SJ, Campos H, Moye LA, Sacks FM: LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003; 23: 853-858. (Pubitemid 36566177)
12. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ: High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004; 24: 2181-2187. (Pubitemid 39482449)
13. Luc G, Bard JM, Ferriéres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiére P: Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: The PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 2002; 22: 1155-1161. (Pubitemid 34764867)
14. Puchois P, Kandoussi A, Fievet P, Fourrier JL, Bertrand M, Koren E, Fruchart JC: Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987; 68: 35-40. (Pubitemid 17151103)
15. Attman PO, Alaupovic P: Lipid and apolipoprotein profiles of uremic dyslipoproteinemia - relation to renal function and dialysis. Nephron 1991; 57: 401-410.
16. Samuelsson O, Attman PO, Knight-Gibson C, Kron B, Larsson R, Mulec H, Weiss L, Alaupovic P: Lipoprotein abnormalities without hyperlipidaemia in moderate renal insufficiency. Nephrol Dial Transplant 1994; 9: 1580-1585. (Pubitemid 24344773)
17. Alhadad A, Guron G, Fortuna-Nowakowska E, Saeed A, Mattiasson I, Jensen G, Lindblad B, Gottsäter A, Herlitz H: Renal angioplasty causes a rapid transient increase in inflammatory biomarkers, but reduced levels of interleukin- 6 and endothelin-1 1 month after intervention. J Hypertens 2007; 25: 1907-1914. (Pubitemid 47356632)
18. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254. (Pubitemid 46768608)
19. Samuelsson O, Attman PO, Knight-Gibson C, Mulec H, Weiss L, Alaupovic P: Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. Am J Kidney Dis 2002; 39: 67-75. (Pubitemid 34062498)
20. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
21. Marz W, Trommlitz M, Gross W: Differential turbidimetric assay for subpopulations of lipoproteins containing apolipoprotein A-I. J Clin Chem Clin Biochem 1988; 26: 573-578.
22. Alaupovic P, Attman PO, Knight-Gibson C, Mulec H, Weiss L, Samuelsson O: Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency. Kidney Int 2006; 69: 1865-1871. (Pubitemid 43739217)
23. Alaupovic P, Hodis HN, Knight-Gibson C, Mack WJ, LaBree L, Cashin-Hemphill L, Corder CN, Kramsch DM, Blankenhorn DH: Effects of lovastatin on ApoA- and ApoB-containing lipoproteins: Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS). Arterioscler Thromb 1994; 14: 1906-1913.
24. de Boer IH, Astor BC, Kramer H, Palmas W, Seliger SL, Shlipak MG, Siscovick DS, Tsai MY, Kestenbaum B: Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol 2008; 3: 125-132.
25. Hiukka A, Fruchart-Najib J, Leinonen E, Hilden H, Fruchart JC, Taskinen MR: Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes. Diabetologia 2005; 48: 1207-1215. (Pubitemid 40909658)
26. Bard JM, Parra HJ, Camare R, et al: A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 1992; 41: 498-503.
27. März W, Scharnagl H, Abletshauser C, Hoffmann MM, Berg A, Keul J, Wieland H, Baumstark MW: Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation 2001; 103: 1942-1948. (Pubitemid 32322220)
28. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP: Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: Lipid and nonlipid factors. Circulation 1990; 81: 470-476. (Pubitemid 20055954)
29. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN: The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997; 17: 715-722. (Pubitemid 27169133)
30. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E: VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol And Recurrent Events (CARE) trial. Circulation 2000; 102: 1886-1892.
31. Scheffer PG, Teerlink T, Dekker JM, Bos G, Nijpels G, Diamant M, Kostense PJ, Stehouwer CD, Heine RJ: Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: The Hoorn Study. Clin Chem 2008; 54: 1325-1330.
32. Wang CS, McConathy WJ, Kloer HU, Alaupovic P: Modulation of lipoprotein lipase activity by apolipoproteins: Effect of apolipoprotein C-III. J Clin Invest 1985; 75: 384-390. (Pubitemid 15143476)
33. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM: Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006; 114: 681-687. (Pubitemid 44252310)
34. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM: Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 2006; 113: 691-700.
35. Kawakami A, Osaka M, Tani M, Azuma H, Sacks FM, Shimokado K, Yoshida M: Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 2008; 118: 731-742.
36. Barter PJ, Rye KA: Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 2008; 28: 39-46.
37. Schuster H, Fagerberg B, Edwards S, Halmos T, Lopatynski J, Stender S, Birketvedt GS, Tonstad S, Gause-Nilsson I, Halldórsdóttir S, Ohman KP, SIR Investigators: Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Atherosclerosis 2008; 197: 355-362. (Pubitemid 351273258)